1. Home
  2. VYNE vs MXE Comparison

VYNE vs MXE Comparison

Compare VYNE & MXE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VYNE
  • MXE
  • Stock Information
  • Founded
  • VYNE 2003
  • MXE 1990
  • Country
  • VYNE United States
  • MXE United States
  • Employees
  • VYNE N/A
  • MXE N/A
  • Industry
  • VYNE Biotechnology: Pharmaceutical Preparations
  • MXE Finance Companies
  • Sector
  • VYNE Health Care
  • MXE Finance
  • Exchange
  • VYNE Nasdaq
  • MXE Nasdaq
  • Market Cap
  • VYNE 41.9M
  • MXE 36.6M
  • IPO Year
  • VYNE 2018
  • MXE N/A
  • Fundamental
  • Price
  • VYNE $2.32
  • MXE $8.54
  • Analyst Decision
  • VYNE Strong Buy
  • MXE
  • Analyst Count
  • VYNE 2
  • MXE 0
  • Target Price
  • VYNE $6.88
  • MXE N/A
  • AVG Volume (30 Days)
  • VYNE 129.4K
  • MXE 5.8K
  • Earning Date
  • VYNE 02-27-2025
  • MXE 01-01-0001
  • Dividend Yield
  • VYNE N/A
  • MXE 2.66%
  • EPS Growth
  • VYNE N/A
  • MXE N/A
  • EPS
  • VYNE N/A
  • MXE N/A
  • Revenue
  • VYNE $493,000.00
  • MXE N/A
  • Revenue This Year
  • VYNE $28.30
  • MXE N/A
  • Revenue Next Year
  • VYNE N/A
  • MXE N/A
  • P/E Ratio
  • VYNE N/A
  • MXE N/A
  • Revenue Growth
  • VYNE 39.27
  • MXE N/A
  • 52 Week Low
  • VYNE $1.57
  • MXE $8.40
  • 52 Week High
  • VYNE $4.30
  • MXE $11.51
  • Technical
  • Relative Strength Index (RSI)
  • VYNE 36.13
  • MXE 57.56
  • Support Level
  • VYNE $2.34
  • MXE $8.28
  • Resistance Level
  • VYNE $3.00
  • MXE $8.43
  • Average True Range (ATR)
  • VYNE 0.27
  • MXE 0.15
  • MACD
  • VYNE -0.08
  • MXE 0.05
  • Stochastic Oscillator
  • VYNE 8.24
  • MXE 94.69

About VYNE VYNE Therapeutics Inc.

VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.

About MXE Mexico Equity and Income Fund Inc. (The)

Mexico Equity and Income Fund Inc is a closed-end, non-diversified management investment company. It maintains an investment objective of long-term capital appreciation through investments in securities, primarily equity, listed on the Mexican Stock Exchange. The company provides a vehicle to investors who wish to invest in Mexican companies through a managed non-diversified portfolio as part of their overall investment program.

Share on Social Networks: